In the BioHarmony Drug Report Database
Olodaterol
Striverdi Respimat (olodaterol) is a small molecule pharmaceutical. Olodaterol was first approved as Striverdi Respimat on 2014-07-31. It is used to treat chronic bronchitis and pulmonary emphysema in the USA. The pharmaceutical is active against beta-2 adrenergic receptor. Striverdi respimat’s patents are valid until 2030-10-16 (FDA).
Trade Name
|
Striverdi Respimat |
|---|---|
Common Name
|
olodaterol |
ChEMBL ID
|
CHEMBL605846 |
Indication
|
chronic bronchitis, pulmonary emphysema |
Drug Class
|
Bronchodilators (phenethylamine derivatives) |
Image (chem structure or protein)